PANALDINE Side Effects

6163612-3 | Disease Progression, Gastrointestinal Haemorrhage, Rash
on Mar 23, 2009 Male patient from JAPAN , weighting 141.3 lb, was diagnosed with myocardial infarction, lung adenocarcinoma and was treated with Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression, gastrointestinal haemorrhage, rash (What is rash?). Panaldine dosage: . During the same period patient was treated with ERLOTINIB (View Erlotinib Review and Erlotinib Label ), ASPIRIN (Form: Enteric) (View Aspirin Review and Aspirin Label ), AMLODIN (View Amlodin Review and Amlodin Label ).

6140190-6 |
Patient was taking Panaldine (View Usage). on Mar 25, 2009 from JAPAN Additional patient health information: Male patient , weighting 143.3 lb, was diagnosed with cerebral infarction and. Panaldine dosage: 100 Mg. During the same period patient was treated with SIMVASTATIN (10 Mg) (View Simvastatin Review and Simvastatin Label ), CLOPIDOGREL (75 Mg) (View Clopidogrel Review and Clopidogrel Label ).

5688822-0 | Agranulocytosis, Cerebrovascular Disorder, Dysarthria, Hypotension, Leukopenia, Malaise, Sepsis
Adverse event was reported on Sep 12, 2001 by a Male patient taking Panaldine (View Usage) (Dosage: ) was diagnosed with acute myocardial infarction, gastritis and. Location: FRANCE , 73 years of age, After Panaldine was administered, patient had the following side effects: agranulocytosis, cerebrovascular disorder, dysarthria, hypotension, leukopenia, malaise, sepsis (What is sepsis?). During the same period patient was treated with PROPACALL (View Propacall Review and Propacall Label ), BUFFERIN (View Bufferin Review and Bufferin Label ), ITOROL (View Itorol Review and Itorol Label ), TENORMIN (View Tenormin Review and Tenormin Label ), FRANDOL (View Frandol Review and Frandol Label ), HARNAL (View Harnal Review and Harnal Label ), LIPITOR (View Lipitor Review and Lipitor Label ), STOGAR (View Stogar Review and Stogar Label ). Patient was hospitalized.

5685064-X | Blood Bilirubin Increased, Cerebral Arteriosclerosis, Cholestasis, Coma Hepatic, Dementia, Depressed Level Of Consciousness, Headache, Hepatic Enzyme Increased, Hepatic Failure
on Apr 05, 2000 Male patient from FRANCE , 70 years of age, was diagnosed with transient ischaemic attack, hypertension, insomnia and was treated with Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, cerebral arteriosclerosis, cholestasis, coma hepatic, dementia (What is dementia?), depressed level of consciousness, headache (What is headache?), hepatic enzyme increased, hepatic failure. Panaldine dosage: . During the same period patient was treated with PERSANTINE (View Persantine Review and Persantine Label ), GLYCYRON (View Glycyron Review and Glycyron Label ), NORVASC (View Norvasc Review and Norvasc Label ), MYSOLINE (View Mysoline Review and Mysoline Label ), INDOMETHACIN (Tradename Reported As Intedaru) (View Indomethacin Review and Indomethacin Label ), RHYTHMY (View Rhythmy Review and Rhythmy Label ), NU LOTAN (View Nu-lotan Review and Nu-lotan Label ). Patient was hospitalized.


5672296-X | Neutrophil Count Decreased
on Mar 12, 2008 Male patient from JAPAN , 58 years of age, was treated with Panaldine (View Usage). Patient had the following side effects: neutrophil count decreased. Panaldine dosage: . During the same period patient was treated with ASPIRIN (Unk, Unk) (View Aspirin Review and Aspirin Label ), TAKEPRON (View Takepron Review and Takepron Label ), FLUVASTATIN (View Fluvastatin Review and Fluvastatin Label ), DIOVAN (View Diovan Review and Diovan Label ). Patient was hospitalized.

5632927-7 | Neutrophil Count Decreased
Patient was taking Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: neutrophil count decreased on Feb 12, 2008 from JAPAN Additional patient health information: Male patient , 58 years of age, . Panaldine dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), FLUVASTATIN (View Fluvastatin Review and Fluvastatin Label ), DIOVAN (View Diovan Review and Diovan Label ). Patient was hospitalized.

5577965-8 | Eczema, Hepatic Function Abnormal, Hepatocellular Damage
Adverse event was reported on Dec 20, 2007 by a Male patient taking Panaldine (View Usage) (Dosage: ) . Location: FRANCE , 79 years of age, Patient experienced the following unwanted or unexpected effects: eczema (What is eczema?), hepatic function abnormal, hepatocellular damage. Patient was hospitalized.

5572993-0 | Agranulocytosis, Pharyngeal Ulceration, Pharyngolaryngeal Pain, Pyrexia, Stomatitis
on Dec 11, 2007 Male patient from FRANCE , 47 years of age, was diagnosed with cerebral infarction and was treated with Panaldine (View Usage). Patient had the following side effects: agranulocytosis, pharyngeal ulceration, pharyngolaryngeal pain, pyrexia, stomatitis. Panaldine dosage: . During the same period patient was treated with CEROCRAL (View Cerocral Review and Cerocral Label ). Patient was hospitalized.

5534423-4 | Dysgeusia, Loss Of Consciousness
on Nov 20, 2007 Male patient from FRANCE , 72 years of age, was diagnosed with percutaneous coronary intervention and was treated with Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: dysgeusia, loss of consciousness. Panaldine dosage: .

5525652-4 | Hepatic Function Abnormal, Interstitial Lung Disease, Pneumocystis Jiroveci Pneumonia
Patient was taking Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic function abnormal, interstitial lung disease, pneumocystis jiroveci pneumonia on Nov 14, 2007 from FRANCE Additional patient health information: Female patient , 67 years of age, . Panaldine dosage: . Patient was hospitalized.

5525631-7 | Hepatic Function Abnormal, Interstitial Lung Disease, Pneumocystis Jiroveci Pneumonia
Adverse event was reported on Nov 14, 2007 by a Female patient taking Panaldine (View Usage) (Dosage: ) . Location: FRANCE , 67 years of age, Patient had the following side effects: hepatic function abnormal, interstitial lung disease, pneumocystis jiroveci pneumonia. Patient was hospitalized.

5523564-3 | Anaemia, Toxic Epidermal Necrolysis, Upper Gastrointestinal Haemorrhage
on Nov 06, 2007 Male patient from FRANCE , 53 years of age, was diagnosed with myocardial infarction, ventricular tachycardia, gastric ulcer haemorrhage, infection (What is infection?), diabetes mellitus and was treated with Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: anaemia, toxic epidermal necrolysis, upper gastrointestinal haemorrhage. Panaldine dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), MEXITIL (View Mexitil Review and Mexitil Label ), OMEPRAL (View Omepral Review and Omepral Label ), CARBENIN (Route:intravenous Nos) (View Carbenin Review and Carbenin Label ), MINOCYCLINE HCL (Route:intravenous Nos) (View Minocycline Hcl Review and Minocycline Hcl Label ), INSULIN (View Insulin Review and Insulin Label ), ZYLORIC (View Zyloric Review and Zyloric Label ). Patient was hospitalized.

5523498-4 | Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts And Leukoencephalopathy, Cerebral Infarction, Dementia, Putamen Haemorrhage
on Nov 09, 2007 Male patient from FRANCE , 47 years of age, was diagnosed with cerebral infarction and was treated with Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, cerebral infarction, dementia (What is dementia?), putamen haemorrhage. Panaldine dosage: . During the same period patient was treated with AMANTADINE HCL (View Amantadine Hcl Review and Amantadine Hcl Label ). Patient was hospitalized and became disabled.

5522073-5 | Condition Aggravated, Rash Pruritic
Patient was taking Panaldine (View Usage). Patient had the following side effects: condition aggravated, rash pruritic on Nov 05, 2007 from FRANCE Additional patient health information: Female patient , 75 years of age, weighting 143.3 lb, . Panaldine dosage: Frequency Reported As Every Day.. During the same period patient was treated with PLAVIX (Frequency Reported As Every Day) (View Plavix Review and Plavix Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), SOL MELCORT (Dose Reported As 500/125mg) (View Sol-melcort Review and Sol-melcort Label ), SOLDEM (View Soldem Review and Soldem Label ), RESCULA (View Rescula Review and Rescula Label ), MIKELAN (View Mikelan Review and Mikelan Label ), FLUMETHOLON (View Flumetholon Review and Flumetholon Label ). Patient was hospitalized.

5519254-3 | Anaemia, Hepatic Enzyme Increased, Pancytopenia, Pneumonia, Toxic Epidermal Necrolysis
Adverse event was reported on Nov 06, 2007 by a Male patient taking Panaldine (View Usage) (Dosage: Indication For Use: Coronary Artery Stent Insertion/angina Pectoris.) was diagnosed with angina pectoris, gastric ulcer, hypertension and. Location: FRANCE , 71 years of age, After Panaldine was administered, patient had the following side effects: anaemia, hepatic enzyme increased, pancytopenia, pneumonia (What is pneumonia?), toxic epidermal necrolysis. During the same period patient was treated with OMEPRAL (View Omepral Review and Omepral Label ), DIOVAN (View Diovan Review and Diovan Label ), SIGMART (View Sigmart Review and Sigmart Label ), BAYASPIRIN (View Bayaspirin Review and Bayaspirin Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ).

5517171-6 | Hepatic Function Abnormal, Interstitial Lung Disease, Pneumocystis Jiroveci Pneumonia
on Nov 01, 2007 Female patient from FRANCE , 67 years of age, was treated with Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic function abnormal, interstitial lung disease, pneumocystis jiroveci pneumonia. Panaldine dosage: . Patient was hospitalized.

5517165-0 | Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts And Leukoencephalopathy, Cerebral Infarction, Dementia, Putamen Haemorrhage
on Nov 02, 2007 Male patient from FRANCE , 47 years of age, was diagnosed with cerebral infarction and was treated with Panaldine (View Usage). Patient had the following side effects: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, cerebral infarction, dementia (What is dementia?), putamen haemorrhage. Panaldine dosage: . During the same period patient was treated with AMANTADINE HCL (View Amantadine Hcl Review and Amantadine Hcl Label ). Patient was hospitalized and became disabled.

5234375-0 | Eczema
Patient was taking Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: eczema (What is eczema?) on Jan 30, 2007 from FRANCE Additional patient health information: Male patient , 55 years of age, was diagnosed with angina pectoris and. Panaldine dosage: . During the same period patient was treated with NICORANDIL (View Nicorandil Review and Nicorandil Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

5226300-3 | Hepatic Enzyme Increased, Laboratory Test Abnormal, Liver Disorder
Adverse event was reported on Jan 23, 2007 by a Male patient taking Panaldine (View Usage) (Dosage: ) was diagnosed with cerebral infarction and. Location: FRANCE , 80 years of age, Patient experienced the following unwanted or unexpected effects: hepatic enzyme increased, laboratory test abnormal, liver disorder. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), MICARDIS (View Micardis Review and Micardis Label ), GASTER (View Gaster Review and Gaster Label ).

5215683-6 | Blue Toe Syndrome, Fat Embolism, Liver Disorder, Shock
on Jan 11, 2007 Male patient from FRANCE , 69 years of age, was diagnosed with coronary artery bypass (What is coronary artery bypass?), hypertension and was treated with Panaldine (View Usage). Patient had the following side effects: blue toe syndrome, fat embolism, liver disorder, shock. Panaldine dosage: Other Indication: Coronary Artery Bypass/ Postsurgical State.. During the same period patient was treated with BUFFERIN (View Bufferin Review and Bufferin Label ), WARFARIN SODIUM (Other Reported Indication: Postsurgical State) (View Warfarin Sodium Review and Warfarin Sodium Label ), AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), ADALAT (Dose Reported As 40 Mg.) (View Adalat Review and Adalat Label ), NU LOTAN (View Nu-lotan Review and Nu-lotan Label ).

5208061-7 | Agranulocytosis, Alanine Aminotransferase Increased, Chills, Gamma-glutamyltransferase Increased, Granulocytopenia, Pharyngitis, Pyrexia
on Jan 08, 2007 Male patient from FRANCE , 65 years of age, was diagnosed with angiopathy, myocardial infarction, coronary arterial stent insertion, angina pectoris, diabetes mellitus and was treated with Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: agranulocytosis, alanine aminotransferase increased, chills, gamma-glutamyltransferase increased, granulocytopenia, pharyngitis, pyrexia. Panaldine dosage: Other Reported Indication: Thrombosis Prophylaxis After Coronary Arterial Stent Insertion. During the same period patient was treated with GASTER (View Gaster Review and Gaster Label ), TICLOPIDINE HYDROCHLORIDE (Reported As Paraclodin.) (View Ticlopidine Hydrochloride Review and Ticlopidine Hydrochloride Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), NICORANDIL (View Nicorandil Review and Nicorandil Label ), MEVALOTIN (View Mevalotin Review and Mevalotin Label ), SIGMART (View Sigmart Review and Sigmart Label ), FAMOTIDINE (Reported As Gasdock) (View Famotidine Review and Famotidine Label ), NOVORAPID (View Novorapid Review and Novorapid Label ). Patient was hospitalized.

5205765-7 | Interstitial Lung Disease
Patient was taking Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease on Jan 09, 2007 from FRANCE Additional patient health information: Male patient , 77 years of age, weighting 141.1 lb, was diagnosed with thrombosis prophylaxis, hypertension, gastric ulcer and. Panaldine dosage: Other Indications: Percutaneous Transluminal Coronary Angioplasty, Thrombosis Prophylaxis.. During the same period patient was treated with EUGLUCON (View Euglucon Review and Euglucon Label ), BUFFERIN (Other Indication Thrombosis Prophylaxis After Pci) (View Bufferin Review and Bufferin Label ), RENIVACE (View Renivace Review and Renivace Label ), OMEPRAL (View Omepral Review and Omepral Label ), DIOVAN (View Diovan Review and Diovan Label ). Patient was hospitalized.

5203468-6 | Coronary Angioplasty, Diarrhoea, Oculomucocutaneous Syndrome, Pyrexia, Vomiting
Adverse event was reported on Jan 02, 2007 by a Male patient taking Panaldine (View Usage) (Dosage: ) was diagnosed with angina pectoris, gastric ulcer and. Location: FRANCE , 40 years of age, Patient had the following side effects: coronary angioplasty, diarrhoea, oculomucocutaneous syndrome, pyrexia, vomiting. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), OMEPRAL (View Omepral Review and Omepral Label ). Patient was hospitalized.

5202175-3 | Fat Embolism
on Jan 03, 2007 Male patient from FRANCE , 65 years of age, was treated with Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: fat embolism. Panaldine dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ).

5198947-4 | Cholestasis, Hepatic Function Abnormal, Hepatocellular Damage, Leukopenia
on Jun 28, 2006 Male patient from FRANCE , 58 years of age, was diagnosed with myocardial infarction and was treated with Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: cholestasis, hepatic function abnormal, hepatocellular damage, leukopenia. Panaldine dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), GASTER D (View Gaster D Review and Gaster D Label ), MAGLAX (View Maglax Review and Maglax Label ), NU LOTAN (View Nu-lotan Review and Nu-lotan Label ), ARTIST (View Artist Review and Artist Label ), MEVALOTIN (View Mevalotin Review and Mevalotin Label ), TAKEPRON (View Takepron Review and Takepron Label ), HERBESSER (View Herbesser Review and Herbesser Label ). Patient was hospitalized.

5196917-3 | Nasopharyngeal Disorder, Neutrophil Count Decreased, Pharyngolaryngeal Pain, Pyrexia, White Blood Cell Count Decreased
Patient was taking Panaldine (View Usage). Patient had the following side effects: nasopharyngeal disorder, neutrophil count decreased, pharyngolaryngeal pain, pyrexia, white blood cell count decreased on Dec 22, 2006 from FRANCE Additional patient health information: Male patient , 63 years of age, was diagnosed with thrombosis prophylaxis and. Panaldine dosage: Further Indications: Stent Placement And Acute Myocardial Infarction.. Patient was hospitalized.

5196901-X | Cytolytic Hepatitis, Hepatic Function Abnormal, Hepatitis Cholestatic, Rash Erythematous, Urine Colour Abnormal
Adverse event was reported on Dec 27, 2006 by a Female patient taking Panaldine (View Usage) (Dosage: ) was diagnosed with transient ischaemic attack, osteoporosis (What is osteoporosis?), cerebrovascular disorder and. Location: FRANCE , 75 years of age, After Panaldine was administered, patient had the following side effects: cytolytic hepatitis, hepatic function abnormal, hepatitis cholestatic, rash erythematous, urine colour abnormal. During the same period patient was treated with EPADEL (View Epadel Review and Epadel Label ), ALFACALCIDOL (View Alfacalcidol Review and Alfacalcidol Label ), GLAKAY (View Glakay Review and Glakay Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), JUVELA NICOTINATE (View Juvela Nicotinate Review and Juvela Nicotinate Label ). Patient was hospitalized.

5195730-0 | Interstitial Lung Disease, Lymphocyte Stimulation Test Positive
on Dec 20, 2006 Male patient from FRANCE , 77 years of age, weighting 141.1 lb, was diagnosed with acute myocardial infarction, hypertension, gastric ulcer and was treated with Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease, lymphocyte stimulation test positive. Panaldine dosage: Other Indications: Percutaneous Transluminal Coronary Angioplasty, Thrombosis Prophylaxis.. During the same period patient was treated with EUGLUCON (View Euglucon Review and Euglucon Label ), BUFFERIN (Other Indication Thrombosis Prophylaxis After Pci) (View Bufferin Review and Bufferin Label ), RENIVACE (View Renivace Review and Renivace Label ), OMEPRAL (View Omepral Review and Omepral Label ), DIOVAN (View Diovan Review and Diovan Label ). Patient was hospitalized.

5181101-X | Interstitial Lung Disease
on Dec 12, 2006 Male patient from FRANCE , 76 years of age, was treated with Panaldine (View Usage). Patient had the following side effects: interstitial lung disease. Panaldine dosage: . During the same period patient was treated with LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), LATAMOXEF (View Latamoxef Review and Latamoxef Label ). Patient was hospitalized.

5176409-8 | Interstitial Lung Disease
Patient was taking Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: interstitial lung disease on Dec 01, 2006 from FRANCE Additional patient health information: Male patient , 77 years of age, was diagnosed with diabetes mellitus, hypertension, thrombosis prophylaxis and. Panaldine dosage: . During the same period patient was treated with EUGLUCON (View Euglucon Review and Euglucon Label ), DIOVAN (View Diovan Review and Diovan Label ), BUFFERIN (View Bufferin Review and Bufferin Label ), OMEPRAL (View Omepral Review and Omepral Label ). Patient was hospitalized.

5174159-5 | Interstitial Lung Disease
Adverse event was reported on Nov 21, 2006 by a Male patient taking Panaldine (View Usage) (Dosage: ) was diagnosed with acute myocardial infarction, hypertension, gastric ulcer and. Location: JAPAN , 77 years of age, weighting 141.1 lb, Patient experienced the following unwanted or unexpected effects: interstitial lung disease. During the same period patient was treated with EUGLUCON (View Euglucon Review and Euglucon Label ), BUFFERIN (View Bufferin Review and Bufferin Label ), RENIVACE (View Renivace Review and Renivace Label ), OMEPRAL (View Omepral Review and Omepral Label ), DIOVAN (View Diovan Review and Diovan Label ). Patient was hospitalized.

5169896-2 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Chromaturia, Gamma-glutamyltransferase Increased, Hepatic Enzyme Increased, Hepatic Function Abnormal, Liver Disorder
on Nov 21, 2006 Female patient from FRANCE , 88 years of age, was diagnosed with cerebral infarction, hypertension, gastritis prophylaxis and was treated with Panaldine (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, chromaturia, gamma-glutamyltransferase increased, hepatic enzyme increased, hepatic function abnormal, liver disorder. Panaldine dosage: . During the same period patient was treated with NORVASC (View Norvasc Review and Norvasc Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), ORUDIS (View Orudis Review and Orudis Label ), ALSAZULENE (View Alsazulene Review and Alsazulene Label ).

5168409-9 | Acute Myocardial Infarction, Interstitial Lung Disease
on Dec 01, 2006 Male patient from FRANCE , 77 years of age, was diagnosed with diabetes mellitus, hypertension, thrombosis prophylaxis and was treated with Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: acute myocardial infarction, interstitial lung disease. Panaldine dosage: . During the same period patient was treated with EUGLUCON (View Euglucon Review and Euglucon Label ), DIOVAN (View Diovan Review and Diovan Label ), BUFFERIN (View Bufferin Review and Bufferin Label ), OMEPRAL (View Omepral Review and Omepral Label ). Patient was hospitalized.

5162906-8 | Alveolitis Allergic, Cough, Dyspnoea, Interstitial Lung Disease, Lymphocyte Stimulation Test Positive
Patient was taking Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: alveolitis allergic, cough, dyspnoea, interstitial lung disease, lymphocyte stimulation test positive on Nov 09, 2006 from FRANCE Additional patient health information: Male patient , 59 years of age, was diagnosed with cerebral infarction, hypertension, diabetes mellitus and. Panaldine dosage: . During the same period patient was treated with LIPITOR (View Lipitor Review and Lipitor Label ), CALBLOCK (View Calblock Review and Calblock Label ), OLMETEC (View Olmetec Review and Olmetec Label ), NOVORAPID (16 Units Am And 6 Units Pm.) (View Novorapid Review and Novorapid Label ). Patient was hospitalized.

5162900-7 | Erythema Multiforme, Pharyngolaryngeal Discomfort, Rash Pruritic
Adverse event was reported on Sep 04, 2006 by a Male patient taking Panaldine (View Usage) (Dosage: ) was diagnosed with myocardial infarction, hypertension, pancreatitis, ventricular extrasystoles, gastric ulcer haemorrhage and. Location: FRANCE , 42 years of age, Patient had the following side effects: erythema multiforme, pharyngolaryngeal discomfort, rash pruritic. During the same period patient was treated with DIOVAN (View Diovan Review and Diovan Label ), PRAVASTATIN SODIUM (View Pravastatin Sodium Review and Pravastatin Sodium Label ), MESITAT (View Mesitat Review and Mesitat Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), ENZYMES (Reported As Shin Dreiase.) (View Enzymes Review and Enzymes Label ), OMEPRAL (View Omepral Review and Omepral Label ), LOXONIN (View Loxonin Review and Loxonin Label ). Patient was hospitalized.

5154039-1 | Alveolitis Allergic, Cough, Dyspnoea
on Nov 09, 2006 Male patient from FRANCE , 59 years of age, was diagnosed with cerebral infarction and was treated with Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: alveolitis allergic, cough, dyspnoea. Panaldine dosage: . During the same period patient was treated with LIPITOR (View Lipitor Review and Lipitor Label ). Patient was hospitalized.

5152304-5 | Gamma-glutamyltransferase Increased, Hepatocellular Damage, Liver Disorder
on Jun 23, 2006 Male patient from FRANCE , 64 years of age, was diagnosed with angina pectoris and was treated with Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: gamma-glutamyltransferase increased, hepatocellular damage, liver disorder. Panaldine dosage: Additional Indication: Dilated Cardiomyopathy. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), MICARDIS (View Micardis Review and Micardis Label ), LASIX (View Lasix Review and Lasix Label ), ACINON (View Acinon Review and Acinon Label ), ALDACTONE (View Aldactone Review and Aldactone Label ). Patient was hospitalized.

5150438-2 | Agranulocytosis, Hyperbilirubinaemia, Pyrexia
Patient was taking Panaldine (View Usage). Patient had the following side effects: agranulocytosis, hyperbilirubinaemia, pyrexia on Nov 06, 2006 from FRANCE Additional patient health information: Male patient , 59 years of age, was diagnosed with thrombosis prophylaxis and. Panaldine dosage: . During the same period patient was treated with ARTIST (View Artist Review and Artist Label ), ANCARON (View Ancaron Review and Ancaron Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ). Patient was hospitalized.

5146162-2 | Acidosis, Blood Pressure Diastolic Decreased, Blood Pressure Increased, Cyanosis, Haematoma, Haemodialysis, Haemoglobin Decreased, Headache, Hepatic Failure
Adverse event was reported on Oct 16, 2006 by a Female patient taking Panaldine (View Usage) (Dosage: Inidcation Also Reported As Stent Placement) was diagnosed with arteriosclerosis obliterans, reflux oesophagitis, hypertension, coronary arterial stent insertion, rheumatoid arthritis (What is rheumatoid arthritis?) and. Location: FRANCE , 65 years of age, After Panaldine was administered, patient had the following side effects: acidosis, blood pressure diastolic decreased, blood pressure increased, cyanosis, haematoma, haemodialysis, haemoglobin decreased, headache (What is headache?), hepatic failure. During the same period patient was treated with LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), RENIVACE (View Renivace Review and Renivace Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), PREDONINE (View Predonine Review and Predonine Label ), LAC B (View Lac B Review and Lac B Label ), BLOPRESS (View Blopress Review and Blopress Label ), PERDIPINE (Given On Dialytic Day.) (View Perdipine Review and Perdipine Label ).

5146128-2 | Interstitial Lung Disease
on Jan 31, 2006 Male patient from FRANCE , 81 years of age, was diagnosed with thrombosis prophylaxis and was treated with Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease. Panaldine dosage: Other Indications: Stent Placement/ischaemic Heart Disease.. During the same period patient was treated with CILOSTAZOL (View Cilostazol Review and Cilostazol Label ). Patient was hospitalized.

5144204-1 | Leukopenia, Neutropenia, Pyrexia, Thrombocytopenia
on Oct 02, 2006 Male patient from FRANCE , 74 years of age, was diagnosed with thrombosis prophylaxis and was treated with Panaldine (View Usage). Patient had the following side effects: leukopenia, neutropenia, pyrexia, thrombocytopenia. Panaldine dosage: Additional Indications, Stent Placement, Acute Myocardial Infarction.. During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), RENIVACE (View Renivace Review and Renivace Label ), LIPITOR (View Lipitor Review and Lipitor Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), ARTIST (View Artist Review and Artist Label ). Patient was hospitalized.

5140136-3 | Hypoxia, Pulmonary Alveolar Haemorrhage
Patient was taking Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: hypoxia, pulmonary alveolar haemorrhage on Oct 06, 2006 from FRANCE Additional patient health information: Female patient , 73 years of age, was diagnosed with thrombosis prophylaxis and. Panaldine dosage: Second Indication Reported As Chronic Atrial Fibrillation. During the same period patient was treated with VASOLAN (View Vasolan Review and Vasolan Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), GASTER D (View Gaster D Review and Gaster D Label ), UNIPHYL (View Uniphyl Review and Uniphyl Label ). Patient was hospitalized.

5140120-X | Headache, Hepatic Function Abnormal, Hepatocellular Damage, Pyrexia
Adverse event was reported on Aug 30, 2006 by a Male patient taking Panaldine (View Usage) (Dosage: ) was diagnosed with myocardial infarction, hyperlipidaemia and. Location: FRANCE , 48 years of age, Patient experienced the following unwanted or unexpected effects: headache (What is headache?), hepatic function abnormal, hepatocellular damage, pyrexia. During the same period patient was treated with LIPITOR (View Lipitor Review and Lipitor Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), ARTIST (View Artist Review and Artist Label ), GASTER D (View Gaster D Review and Gaster D Label ). Patient was hospitalized.

5133715-0 | Hepatic Necrosis, Hypoglycaemia, Liver Disorder, Loss Of Consciousness, Shock, Thrombotic Thrombocytopenic Purpura
on Oct 16, 2006 Female patient from FRANCE , 66 years of age, was diagnosed with thrombosis prophylaxis and was treated with Panaldine (View Usage). Patient had the following side effects: hepatic necrosis, hypoglycaemia, liver disorder, loss of consciousness, shock, thrombotic thrombocytopenic purpura. Panaldine dosage: Inidcation Also Reported As Stent Placement. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ).

5126054-5 | Agranulocytosis, Granulocytopenia, Headache, Pyrexia
on Aug 25, 2006 Male patient from FRANCE , 61 years of age, was diagnosed with cerebral infarction, diabetes mellitus, hypertension and was treated with Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: agranulocytosis, granulocytopenia, headache (What is headache?), pyrexia. Panaldine dosage: . During the same period patient was treated with DAONIL (View Daonil Review and Daonil Label ), ADALAT (View Adalat Review and Adalat Label ), GLUCOBAY (View Glucobay Review and Glucobay Label ), SHOUSAIKOTOU (View Shousaikotou Review and Shousaikotou Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), HALCION (View Halcion Review and Halcion Label ), ALINAMIN (Reported As Alanmin S) (View Alinamin Review and Alinamin Label ). Patient was hospitalized.

5124870-7 | Hypoxia, Pulmonary Alveolar Haemorrhage
Patient was taking Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: hypoxia, pulmonary alveolar haemorrhage on Oct 06, 2006 from FRANCE Additional patient health information: Female patient , 73 years of age, was diagnosed with thrombosis prophylaxis and. Panaldine dosage: Second Indication Reported As Chronic Atrial Fibrillation. During the same period patient was treated with WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ). Patient was hospitalized.

5124827-6 | C-reactive Protein Increased, Influenza Serology Positive, Pyrexia
Adverse event was reported on Sep 21, 2006 by a Male patient taking Panaldine (View Usage) (Dosage: ) was diagnosed with thrombosis prophylaxis and. Location: FRANCE , 79 years of age, Patient had the following side effects: c-reactive protein increased, influenza serology positive, pyrexia. During the same period patient was treated with GASTER D (View Gaster D Review and Gaster D Label ), LANDSEN (View Landsen Review and Landsen Label ), TEGRETOL (View Tegretol Review and Tegretol Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), ARTIST (View Artist Review and Artist Label ), BLOPRESS (View Blopress Review and Blopress Label ), NORVASC (View Norvasc Review and Norvasc Label ), VEGETAMIN (View Vegetamin Review and Vegetamin Label ). Patient was hospitalized.

5120937-8 | Cytolytic Hepatitis, Hepatic Function Abnormal, Hepatitis Cholestatic, Rash Erythematous, Urine Colour Abnormal
on Sep 27, 2006 Female patient from FRANCE , 75 years of age, was diagnosed with transient ischaemic attack, osteoporosis (What is osteoporosis?), cerebrovascular disorder and was treated with Panaldine (View Usage). After Panaldine was administered, patient had the following side effects: cytolytic hepatitis, hepatic function abnormal, hepatitis cholestatic, rash erythematous, urine colour abnormal. Panaldine dosage: . During the same period patient was treated with ETHYL ICOSAPENTATE (View Ethyl Icosapentate Review and Ethyl Icosapentate Label ), ALFACALCIDOL (View Alfacalcidol Review and Alfacalcidol Label ), GLAKAY (View Glakay Review and Glakay Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), JUVELA NICOTINATE (View Juvela Nicotinate Review and Juvela Nicotinate Label ). Patient was hospitalized.

5117597-9 | Pyrexia
on Sep 21, 2006 Male patient from FRANCE , 90 years of age, was diagnosed with angina pectoris and was treated with Panaldine (View Usage). Patient experienced the following unwanted or unexpected effects: pyrexia. Panaldine dosage: . Patient was hospitalized.

5110231-3 | Nasopharyngitis, Urticaria
Patient was taking Panaldine (View Usage). Patient had the following side effects: nasopharyngitis, urticaria on Aug 11, 2006 from FRANCE Additional patient health information: Male patient , 50 years of age, was diagnosed with thrombosis prophylaxis, acute myocardial infarction and. Panaldine dosage: Other Indication Reported Stent Placement, Acute Myocardial Infarction. During the same period patient was treated with ASPIRIN (Other Indications Stent Placement And Acute Myocardial Infarction) (View Aspirin Review and Aspirin Label ), RENIVACE (View Renivace Review and Renivace Label ). Patient was hospitalized.